New pharmacovigilance rules in the EU and their impact on biosimilars and automatic substitution
This article was originally published in SRA
Executive Summary
Burkhard Sträter describes how the new pharmacovigilance requirements for biosimilars will affect member states, doctors, pharmacists and, last but not least, pharmaceutical companies.